查看购物车
  • Traditional Chinese
  • English
  • Japanese
自动注射器市场按用途、技术、给药途径、治疗领域、数量、最终用户和地区划分 - 预测至 2030 年
市场调查报告书
商品编码
1674549

自动注射器市场按用途、技术、给药途径、治疗领域、数量、最终用户和地区划分 - 预测至 2030 年

Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphypaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 384 Pages | 订单完成后即时交付

价格

全球自动注射器市场规模预计将从 2024 年的 14 亿美元成长到 2030 年的 30.2 亿美元，复合年增长率为 13.6%。

自动注射器成品製剂市场预计将从 2024 年的 673 亿美元激增至 2030 年的 1,342.7 亿美元，复合年增长率为 12.2%。

研究范围
调查年份 2022-2030
基准年 2023
预测期 2024-2030
目标单位 金额（美元）及数量（件）
部分 按用途、按技术、按给药途径、按治疗领域、按数量、按最终用户、按地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

根据技术，自动注射器市场进一步细分为手动和自动。由于糖尿病、多发性硬化症和类风湿性关节炎等疾病的发病率上升导致需求增加，手动自动注射器领域在 2023 年占据了市场主导地位。此外，由于成本效益和新兴的治疗应用，未来几年手动自动注射器的整体市场潜力可能会增加。

自动注射器市场的最终用户群包括居家医疗机构、医院/诊所和门诊护理机构。 2023 年，由于居家医疗保健环境中自动注射器的使用越来越多，居家医疗环境领域占了最大的份额。此外，具有成本效益、用户友好的自动注射器设备的推出可能会促进居家医疗领域的成长。在过敏反应等紧急情况下使用自动注射器可能会增加医院和诊所对自动注射器的需求，从而进一步推动市场成长。

2023 年，北美占据了自动注射器市场的主导地位，预计在预测期内仍将占据主导地位。医疗保健基础设施的发展、糖尿病、类风湿性关节炎和多发性硬化症等慢性病的流行以及北美优惠的报销政策正在影响自动注射器的使用并促进市场成长。预计在预测期内，即 2024-2030 年，亚太地区自动注射器市场将以显着的复合年增长率成长。该地区的成长主要得益于大量製药和生物製药公司的存在，以及自动注射器监管核准数量的增加，尤其是在中国、印度和韩国。

本报告研究了全球自动注射器市场，按用途、技术、给药途径、治疗领域、容量、最终用户和地理细分，并提供了参与市场的公司概况。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章 市场概况

  • 介绍
  • 市场动态
  • 影响客户业务的趋势/干扰
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 监管状态
  • 波特五力分析
  • 贸易资料分析
  • 技术分析
  • 专利分析
  • 指标价格分析
  • 2025-2026 年重要会议与活动
  • 投资金筹措场景
  • 主要相关人员和采购标准
  • 生成式人工智慧对自动注射器市场的影响

第 6 章 自动注射器市场（依用途）

  • 介绍
  • 一次性自动注射器
  • 可重复使用的自动注射器

第 7 章 自动注射器市场（依技术分类）

  • 介绍
  • 手动自动注射器
  • 自动注射器

第 8 章 自动注射器市场（依管理途径）

  • 介绍
  • 皮下途径
  • 肌肉注射

第 9 章 自动注射器市场（依治疗领域）

  • 介绍
  • 类风湿性关节炎
  • 糖尿病
  • 多发性硬化症
  • 过敏反应
  • 肥胖
  • 其他的

第 10 章 自动注射器市场（按容量）

  • 介绍
  • 少于3毫升
  • 3毫升以上

第 11 章 自动注射器市场（依最终用户划分）

  • 介绍
  • 居家医疗
  • 医院和诊所
  • 门诊治疗环境

第 12 章 自动注射器市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 其他的
  • 拉丁美洲
    • 巴西
    • 其他的
  • 中东和非洲
    • 海湾合作委员会国家
    • 其他的

第十三章 竞争格局

  • 介绍
  • 2021 年至 2025 年主要参与企业的策略/优势
  • 2021-2023 年收益分析
  • 2023 年市场占有率分析
  • 公司估值矩阵：主要参与企业，2023 年
  • 公司估值矩阵：Start-Ups/中小企业，2023 年
  • 企业估值与财务指标
  • 品牌/产品比较
  • 竞争场景
  • 大容量製剂装置
  • 高黏度配方装置
  • 洞察自动注射器市场的未来重点领域

第十四章 公司简介

  • 主要参与企业：自动注射器市场
    • SHL MEDICAL AG
    • YPSOMED AG
    • BECTON, DICKINSON AND COMPANY（BD）
    • RECIPHARM AB
    • WEST PHARMACEUTICAL SERVICES, INC.
    • PHILLIPS-MEDISIZE
    • HALOZYME, INC.
    • OWEN MUMFORD LTD.
  • 主要参与企业：自动注射器成品配方市场
    • ABBVIE INC.
    • ELI LILLY AND COMPANY
    • AMGEN INC.
    • NOVO NORDISK A/S
    • JOHNSON & JOHNSON SERVICES, INC.
    • SANOFI
    • GSK PLC
  • 其他公司
    • GERRESHEIMER AG
    • HASELMEIER
    • SMC LTD
    • KALEO, INC.
    • SOLTEAM INCORPORATION CO., LTD.
    • ELCAM DRUG DELIVERY DEVICES
    • CROSSJECT
    • JABIL INC.
    • CONGRUENCE MEDICAL SOLUTIONS LLC
    • MIDAS PHARMA GMBH

第十五章 附录

Product Code: MD 6494

The global autoinjectors market is projected to to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to a value of USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%.

Scope of the Report
Years Considered for the Study2022-2030
Base Year2023
Forecast Period2024-2030
Units ConsideredValue (USD) and Volume (Unit)
SegmentsUsage, Technology, Route of Administration, Therapy Area, Volume, and End user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Favorable reimbursement policies in North America and Europe coupled with launch of biosimilars across the globe are some of the factors contributing towards the market growth.

"The manual autoinjectors segment accounted for the largest share in 2023."

On the basis of technology, the autoinjectors market is further segmented into manual, and automatic. The manual autoinjectors segment dominated the market in 2023, owing to the rise in demand due to rising incidence of conditions such as diabetes, multiple sclerosis, and rheumatoid arthritis. Furthermore, cost-effectiveness and expanding new therapeutic applications, is likely to increase their overall market potential for manual autoinjectors in coming years.

"By end user, the home care settings segment accounted for the largest share in the autoinjectors market."

The end user segment in the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. In 2023, the home care settings segment accounted for the largest share owing to increased adoption of autoinjectors at home care settings. Furthermore, cost effectiveness, launch of user friendly autoinjector devices is likely to boost the growth of the home care settings segment. Use of autoinjectors for emergency situations such as anaphylactic reactions is likely to increase demand for autoinjectors in hospitals & clinics further propelling the growth of the market.

"North America: the largest share of the autoinjectors market"

North America dominated the autoinjectors market in 2023 and likely continue dominance during the forecast period. Well-developed healthcare infrastructure, prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis and favourable reimbursement policies in North America are some of the factors influencing the use of autoinjectors subsequently contributing towards market growth. The Asia Pacific autoinjectors market is predicted to grow at the significant CAGR during the forecast period of 2024-2030. The growth of the region is primarily attributed to the presence of large number of pharmaceutical and biopharmaceutical companies and growing number of regulatory apporvals for autoinjectors in the region especially China, India and South Korea.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

  • SHL Medical AG (Switzerland)
  • Ypsomed AG (Switzerland)
  • Becton, Dickinson and Company (BD) (US)
  • Recipharm AB (Sweden)
  • West Pharmaceutical Services, Inc.(US)
  • Phillips-Medisize (US)
  • Halozyme, Inc. (US)
  • Owen Mumford Ltd. (UK)
  • Abbvie Inc. (US)
  • Eli Lilly and Company (US)
  • Amgen Inc. (US)
  • Novo Nordisk A/S (Denmark)
  • Jonhson & Jonhson Services Inc. (US)
  • Sanofi (France)
  • GSK plc (UK)
  • Gerresheimer AG (Germany)
  • Haselmeier (Germany)
  • Oval Medical Technologies Ltd. (UK)
  • Kaleo, Inc. (US)
  • Solteam Incorporation Co., Ltd. (China)
  • Elcam Drug Delivery Devices (Israel)
  • Crossject (France)
  • Jabil, Inc. (US)
  • Congruence Medical Solutions LLC (US)
  • Midas Pharma GMBH (Germany)

Research Coverage:

This research report categorizes the autoinjectors market usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, obesity and other therapy areas), Volume (upto 3ml and above 3 ml) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the autoinjectors market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the autoinjectors market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the autoinjector devices and finished formulations market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising prevalence of chronic diseases, increasing regulatory approvals for autoinjectors, high demand for biologics & biosimilars, growing adoption of self-administered medicines, government support and favorable reimbursement policies), restraints (Focus on needle-free drug delivery systems and prevalence of needle phobia ), opportunities (Impending patent expiry of biological molecules, launch of technologically-advanced autoinjectors) and Challenges (Development of autoinjectors for multiple drug viscosities) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the autoinjectors market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoinjectors market
  • Competitive Assessment: SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), and Novo Nordisk A/S (Denmark) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS & EXCLUSIONS
  • 1.4 STUDY SCOPE
    • 1.4.1 SEGMENTS CONSIDERED
    • 1.4.2 YEARS CONSIDERED
    • 1.4.3 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION METHODOLOGY OF AUTOINJECTORS DEVICES
  • 2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS
    • 2.3.1 INSIGHTS FROM PRIMARY EXPERTS
    • 2.3.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
  • 2.4 MARKET GROWTH RATE PROJECTIONS
  • 2.5 DATA TRIANGULATION
  • 2.6 RESEARCH ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
  • 2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 AUTOINJECTORS MARKET OVERVIEW
  • 4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE AND COUNTRY (2023)
  • 4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION AND COUNTRY (2023)
  • 4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2024 VS. 2030 (USD MILLION)
  • 4.5 AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2023
  • 4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of chronic diseases
      • 5.2.1.2 Increasing regulatory approvals for autoinjectors
      • 5.2.1.3 High demand for biosimilars and biologics
      • 5.2.1.4 Growing adoption of self-administered medicines
      • 5.2.1.5 Government support and favorable reimbursement policies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Focus on needle-free drug delivery systems and prevalence of needle phobia
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Impending patent expiry of biological molecules
      • 5.2.3.2 Launch of technologically advanced autoinjectors
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Development of autoinjectors for multiple drug viscosities
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 VALUE CHAIN ANALYSIS
    • 5.4.1 VALUE CHAIN ANALYSIS: AUTOINJECTOR DEVICE MANUFACTURERS (PLATFORM PROVIDERS)
    • 5.4.2 VALUE CHAIN ANALYSIS: AUTOINJECTOR FINISHED FORMULATION MANUFACTURERS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • 5.6.1 AUTOINJECTOR PROVIDERS
    • 5.6.2 END USERS
    • 5.6.3 REGULATORY BODIES
  • 5.7 REGULATORY LANDSCAPE
    • 5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
      • 5.7.1.1 North America
      • 5.7.1.2 Europe
      • 5.7.1.3 Asia Pacific
      • 5.7.1.4 Rest of the World
    • 5.7.2 REGULATORY FRAMEWORK
      • 5.7.2.1 North America
      • 5.7.2.2 Europe
      • 5.7.2.3 Asia Pacific
      • 5.7.2.4 Rest of the World
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.8.2 BARGAINING POWER OF SUPPLIERS
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 THREAT OF SUBSTITUTES
    • 5.8.5 THREAT OF NEW ENTRANTS
  • 5.9 TRADE DATA ANALYSIS
    • 5.9.1 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS)
    • 5.9.2 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS)
  • 5.10 TECHNOLOGY ANALYSIS
    • 5.10.1 KEY TECHNOLOGIES
      • 5.10.1.1 Injection mechanism technology
      • 5.10.1.2 Electronic and connectivity solutions
    • 5.10.2 ADJACENT TECHNOLOGIES
      • 5.10.2.1 Wearable drug delivery devices
      • 5.10.2.2 Implantable drug delivery systems
    • 5.10.3 COMPLEMENTARY TECHNOLOGIES
      • 5.10.3.1 Power assistance mechanisms
      • 5.10.3.2 Advanced needle technology
  • 5.11 PATENT ANALYSIS
    • 5.11.1 METHODOLOGY
    • 5.11.2 PATENTS APPLIED AND GRANTED, 2014-2025
  • 5.12 INDICATIVE PRICING ANALYSIS
    • 5.12.1 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE
    • 5.12.2 AVERAGE SELLING PRICE, BY USAGE
    • 5.12.3 INDICATIVE PRICING ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY KEY PLAYER
    • 5.12.4 INDICATIVE PRICING ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY REGION
  • 5.13 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.14 INVESTMENT AND FUNDING SCENARIO
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
      • 5.15.1.1 Key stakeholders in buying process for autoinjector devices
      • 5.15.1.2 Key stakeholders in buying process for autoinjector finished formulations
    • 5.15.2 KEY BUYING CRITERIA
      • 5.15.2.1 Key buying criteria for autoinjector devices
      • 5.15.2.2 Key buying criteria for autoinjector finished formulations
  • 5.16 IMPACT OF GENERATIVE AI ON AUTOINJECTORS MARKET

6 AUTOINJECTORS MARKET, BY USAGE

  • 6.1 INTRODUCTION
  • 6.2 DISPOSABLE AUTOINJECTORS
    • 6.2.1 EASE OF USE AND REDUCED RISK OF NEEDLESTICK INJURIES TO PROPEL MARKET GROWTH
  • 6.3 REUSABLE AUTOINJECTORS
    • 6.3.1 COST-EFFECTIVENESS, VERSATILITY, AND SUSTAINABILITY TO FUEL MARKET GROWTH

7 AUTOINJECTORS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 MANUAL AUTOINJECTORS
    • 7.2.1 USER-FRIENDLY DESIGN AND INCREASED PATIENT CONTROL TO AUGMENT MARKET GROWTH
  • 7.3 AUTOMATIC AUTOINJECTORS
    • 7.3.1 EASE OF ACCURATE DOCUMENTATION AND COMPREHENSIVE PATIENT RECORDS TO SUPPORT MARKET GROWTH

8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION

  • 8.1 INTRODUCTION
  • 8.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION
    • 8.2.1 EASE OF USE, RAPID ABSORPTION, AND SUITABILITY FOR SELF-ADMINISTRATION TO AID MARKET GROWTH
  • 8.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION
    • 8.3.1 NEED FOR PRECISE DOSE DELIVERY IN EMERGENCY CLINICAL SETTINGS TO DRIVE MARKET

9 AUTOINJECTORS MARKET, BY THERAPY AREA

  • 9.1 INTRODUCTION
  • 9.2 RHEUMATOID ARTHRITIS
    • 9.2.1 HIGH DISEASE PREVALENCE AND NEED FOR FREQUENT DOSING TO DRIVE MARKET
  • 9.3 DIABETES
    • 9.3.1 LARGE DIABETIC POPULATION AND EASE OF ADMINISTRATION TO STIMULATE DEMAND
  • 9.4 MULTIPLE SCLEROSIS
    • 9.4.1 AVAILABILITY OF COST-EFFECTIVE GENERIC ORAL MULTIPLE SCLEROSIS DRUGS TO LIMIT MARKET GROWTH
  • 9.5 ANAPHYLAXIS
    • 9.5.1 REQUIREMENT FOR PROMPT INITIAL TREATMENT FOR PATIENTS WITH FOOD ALLERGIES TO FUEL MARKET GROWTH
  • 9.6 OBESITY
    • 9.6.1 INCREASING FOCUS ON WEIGHT MANAGEMENT TO BOOST MARKET GROWTH
  • 9.7 OTHER THERAPY AREAS

10 AUTOINJECTORS MARKET, BY VOLUME

  • 10.1 INTRODUCTION
  • 10.2 UP TO 3ML VOLUME AUTOINJECTORS
    • 10.2.1 RISING PREVALENCE OF AUTOIMMUNE DISORDERS AND LONG-TERM CHRONIC DISEASES TO PROPEL MARKET GROWTH
  • 10.3 ABOVE 3ML VOLUME AUTOINJECTORS
    • 10.3.1 INCREASING FOCUS ON COMPLEX TREATMENTS WITH HIGH-VISCOSITY DRUGS TO DRIVE MARKET

11 AUTOINJECTORS MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HOME CARE SETTINGS
    • 11.2.1 COST-EFFECTIVENESS AND INCREASED AVAILABILITY OF HOME CARE SUPPORT SERVICES TO PROPEL MARKET GROWTH
  • 11.3 HOSPITALS & CLINICS
    • 11.3.1 TECHNOLOGICAL ADVANCEMENTS AND AVAILABILITY OF REAL-TIME PATIENT DATA TO SUPPORT MARKET GROWTH
  • 11.4 AMBULATORY CARE SETTINGS
    • 11.4.1 GROWING DEMAND FOR OUTPATIENT SERVICES TO FUEL MARKET GROWTH

12 AUTOINJECTORS MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 US
      • 12.2.1.1 US to dominate North American autoinjectors market during forecast period
    • 12.2.2 CANADA
      • 12.2.2.1 Rising geriatric population and increasing prevalence of food allergies to propel market growth
  • 12.3 EUROPE
    • 12.3.1 GERMANY
      • 12.3.1.1 Favorable government initiatives and regulatory trends to aid market growth
    • 12.3.2 UK
      • 12.3.2.1 High prevalence of allergic conditions and increased incidence of lifestyle diseases to boost market growth
    • 12.3.3 FRANCE
      • 12.3.3.1 High prevalence of diabetes and favorable reimbursement policies to support market
    • 12.3.4 ITALY
      • 12.3.4.1 Rising healthcare expenditure and increasing geriatric population to augment market growth
    • 12.3.5 SPAIN
      • 12.3.5.1 Favorable reimbursement scenario and presence of universal health coverage facility to aid market growth
    • 12.3.6 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 JAPAN
      • 12.4.1.1 Large geriatric population and improved healthcare infrastructure to drive market
    • 12.4.2 CHINA
      • 12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to fuel market growth
    • 12.4.3 INDIA
      • 12.4.3.1 Increasing burden of diabetes and cardiovascular diseases to spur market growth
    • 12.4.4 SOUTH KOREA
      • 12.4.4.1 Increased regulatory approvals and strong clinical pipeline by domestic players to propel market
    • 12.4.5 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 BRAZIL
      • 12.5.1.1 Rising adoption of autoinjectors and growing prevalence of chronic diseases to augment market growth
    • 12.5.2 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 GCC COUNTRIES
      • 12.6.1.1 High healthcare spending capacity and favorable regulatory scenario to drive market
    • 12.6.2 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2021-2025
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOINJECTORS MARKET
  • 13.3 REVENUE ANALYSIS, 2021-2023
    • 13.3.1 REVENUE ANALYSIS: AUTOINJECTOR DEVICES MARKET
    • 13.3.2 REVENUE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET
  • 13.4 MARKET SHARE ANALYSIS, 2023
    • 13.4.1 MARKET SHARE ANALYSIS: AUTOINJECTOR DEVICES MARKET
    • 13.4.2 MARKET SHARE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
      • 13.5.1.1 Stars
      • 13.5.1.2 Emerging leaders
      • 13.5.1.3 Pervasive players
      • 13.5.1.4 Participants
    • 13.5.2 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
      • 13.5.2.1 Stars
      • 13.5.2.2 Emerging leaders
      • 13.5.2.3 Pervasive players
      • 13.5.2.4 Participants
    • 13.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 13.5.3.1 Company footprint
      • 13.5.3.2 Region footprint
      • 13.5.3.3 Usage footprint
      • 13.5.3.4 Volume footprint
      • 13.5.3.5 Route of administration footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 13.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 13.7.1 FINANCIAL METRICS
    • 13.7.2 COMPANY VALUATION
  • 13.8 BRAND/PRODUCT COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS
  • 13.10 DEVICES FOR LARGE-VOLUME FORMULATIONS
  • 13.11 DEVICES FOR HIGHLY VISCOUS FORMULATIONS
  • 13.12 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS: AUTOINJECTOR DEVICES MARKET
    • 14.1.1 SHL MEDICAL AG
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Product launches
        • 14.1.1.3.2 Deals
        • 14.1.1.3.3 Expansions
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Key strengths
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses and competitive threats
    • 14.1.2 YPSOMED AG
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches
        • 14.1.2.3.2 Deals
        • 14.1.2.3.3 Expansions
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 BECTON, DICKINSON AND COMPANY (BD)
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Deals
        • 14.1.3.3.2 Other developments
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Key strengths
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses and competitive threats
    • 14.1.4 RECIPHARM AB
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products offered
    • 14.1.5 WEST PHARMACEUTICAL SERVICES, INC.
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Expansions
    • 14.1.6 PHILLIPS-MEDISIZE
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product launches
    • 14.1.7 HALOZYME, INC.
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products offered
    • 14.1.8 OWEN MUMFORD LTD.
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches
        • 14.1.8.3.2 Deals
        • 14.1.8.3.3 Expansions
  • 14.2 KEY PLAYERS: AUTOINJECTOR FINISHED FORMULATIONS MARKET
    • 14.2.1 ABBVIE INC.
      • 14.2.1.1 Business overview
      • 14.2.1.2 Products offered
      • 14.2.1.3 Recent developments
        • 14.2.1.3.1 Product launches and approvals
    • 14.2.2 ELI LILLY AND COMPANY
      • 14.2.2.1 Business overview
      • 14.2.2.2 Products offered
      • 14.2.2.3 Recent developments
        • 14.2.2.3.1 Product approvals
        • 14.2.2.3.2 Deals
    • 14.2.3 AMGEN INC.
      • 14.2.3.1 Business overview
      • 14.2.3.2 Products offered
      • 14.2.3.3 Recent developments
        • 14.2.3.3.1 Product launches
    • 14.2.4 NOVO NORDISK A/S
      • 14.2.4.1 Business overview
      • 14.2.4.2 Products offered
      • 14.2.4.3 Recent developments
        • 14.2.4.3.1 Product approvals
        • 14.2.4.3.2 Deals
        • 14.2.4.3.3 Expansions
        • 14.2.4.3.4 Other developments
    • 14.2.5 JOHNSON & JOHNSON SERVICES, INC.
      • 14.2.5.1 Business overview
      • 14.2.5.2 Products offered
    • 14.2.6 SANOFI
      • 14.2.6.1 Business overview
      • 14.2.6.2 Products offered
    • 14.2.7 GSK PLC
      • 14.2.7.1 Business overview
      • 14.2.7.2 Products offered
      • 14.2.7.3 Recent developments
        • 14.2.7.3.1 Product approvals
  • 14.3 OTHER PLAYERS
    • 14.3.1 GERRESHEIMER AG
    • 14.3.2 HASELMEIER
    • 14.3.3 SMC LTD
    • 14.3.4 KALEO, INC.
    • 14.3.5 SOLTEAM INCORPORATION CO., LTD.
    • 14.3.6 ELCAM DRUG DELIVERY DEVICES
    • 14.3.7 CROSSJECT
    • 14.3.8 JABIL INC.
    • 14.3.9 CONGRUENCE MEDICAL SOLUTIONS LLC
    • 14.3.10 MIDAS PHARMA GMBH

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 AUTOINJECTORS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON AUTOINJECTORS MARKET
  • TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE, 2020-2024
  • TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS
  • TABLE 5 LIST OF KEY AUTOINJECTOR DEVICE PROVIDERS
  • TABLE 6 LIST OF KEY AUTOINJECTOR FINISHED FORMULATION PRODUCT PROVIDERS
  • TABLE 7 LIST OF KEY END USERS
  • TABLE 8 LIST OF KEY REGULATORY BODIES
  • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 AUTOINJECTORS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 14 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS), 2021-2023 (USD MILLION)
  • TABLE 15 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS), 2021-2023 (USD MILLION)
  • TABLE 16 LIST OF ADVANTAGES AND DISADVANTAGES OF AUTOINJECTOR TECHNOLOGIES
  • TABLE 17 PATENTS FILED, 2014-2024
  • TABLE 18 INNOVATIONS AND PATENT REGISTRATIONS, 2023-2024
  • TABLE 19 INDICATIVE PRICING OF FINISHED FORMULATION PRODUCTS, BY KEY PLAYER, 2023
  • TABLE 20 INDICATIVE PRICING ANALYSIS OF THERAPY AREAS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY REGION, 2023
  • TABLE 21 AUTOINJECTORS MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 22 AUTOINJECTOR DEVICES MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • TABLE 23 AUTOINJECTOR FINISHED FORMULATIONS MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • TABLE 24 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 25 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (MILLION UNITS)
  • TABLE 26 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 27 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 28 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 29 NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 30 EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 32 LATIN AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 33 MIDDLE EAST & AFRICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 34 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 35 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 36 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 38 LATIN AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 39 MIDDLE EAST & AFRICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 40 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 41 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 42 NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 43 EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 45 LATIN AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 46 MIDDLE EAST & AFRICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 47 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 48 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 49 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 51 LATIN AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 52 MIDDLE EAST & AFRICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 53 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 54 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (MILLION UNITS)
  • TABLE 55 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 56 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 57 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 58 NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 59 EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 61 LATIN AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 62 MIDDLE EAST & AFRICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 63 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 64 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 65 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 67 LATIN AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 68 MIDDLE EAST & AFRICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 69 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 70 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 71 NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 72 EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 74 LATIN AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 75 MIDDLE EAST & AFRICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 76 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 77 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 78 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 80 LATIN AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 81 MIDDLE EAST & AFRICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 82 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 83 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (MILLION UNITS)
  • TABLE 84 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 85 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 86 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 87 EUROPE: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 89 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 90 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 91 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 92 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, 2022-2030 (MILLION UNITS)
  • TABLE 93 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 94 EUROPE: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 96 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 97 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 98 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 99 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (MILLION UNITS)
  • TABLE 100 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 101 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 102 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 103 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 104 EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 106 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 107 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 108 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 109 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 110 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 112 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 113 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 114 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 115 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 116 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 117 EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 119 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 120 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 121 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 122 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 123 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 125 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 126 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 127 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 128 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 129 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 130 EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 132 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 133 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 134 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 135 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 136 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 137 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 138 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 139 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 140 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 141 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 142 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 143 EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 145 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 146 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 147 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 148 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 149 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 151 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 152 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 153 AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 154 AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 155 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 156 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 158 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 159 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 160 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 161 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 162 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 163 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 164 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 166 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 167 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 168 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 169 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 170 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 171 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 172 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 173 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 174 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 175 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 177 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 178 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 179 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 180 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (MILLION UNITS)
  • TABLE 181 UP TO 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 182 UP TO 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 183 ABOVE 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 184 ABOVE 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
  • TABLE 185 AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 186 AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 187 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 188 EUROPE: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 190 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 191 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 192 AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 193 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 194 EUROPE: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 195 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 196 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 197 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 198 AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 199 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 200 EUROPE: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 202 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 203 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 204 AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 205 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 206 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 207 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 208 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 209 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 210 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 211 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 212 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 213 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 214 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 215 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 216 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 217 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 218 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 219 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 220 AUTOINJECTORS APPROVED BY US FDA, 2018-2024
  • TABLE 221 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 222 US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 223 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 224 US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 225 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 226 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 227 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 228 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 229 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 230 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 231 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 232 CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 233 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 234 CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 235 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 236 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 237 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 238 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 239 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 240 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 241 EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 242 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 243 EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 244 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 245 EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 246 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 247 EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 248 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 249 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 250 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 251 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 252 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 253 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 254 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 255 GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 256 GERMANY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 257 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 258 GERMANY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 259 GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 260 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 261 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 262 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 263 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 264 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 265 UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 266 UK: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 267 UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 268 UK: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 269 UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 270 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 271 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 272 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 273 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 274 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 275 FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 276 FRANCE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 277 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 278 FRANCE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 279 FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 280 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 281 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 282 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 283 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 284 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 285 ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 286 ITALY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 287 ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 288 ITALY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 289 ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 290 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 291 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 292 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 293 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 294 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 295 SPAIN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 296 SPAIN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 297 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 298 SPAIN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 299 SPAIN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 300 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 301 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 302 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 303 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 304 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 305 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 306 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 307 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 308 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 309 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 310 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 311 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 312 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 313 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 314 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 316 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 318 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 319 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 320 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 321 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 322 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 323 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 324 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 325 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 326 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 327 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 328 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 329 JAPAN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 330 JAPAN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 331 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 332 JAPAN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 333 JAPAN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 334 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 335 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 336 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 337 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 338 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 339 CHINA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 340 CHINA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 341 CHINA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 342 CHINA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 343 CHINA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 344 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 345 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 346 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 347 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 348 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 349 INDIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 350 INDIA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 351 INDIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 352 INDIA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 353 INDIA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 354 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 355 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 356 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 357 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 358 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 359 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 360 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 361 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 362 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 363 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 364 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 365 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 366 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 367 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 368 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 369 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 370 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 371 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 372 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 373 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 374 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 375 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 376 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 377 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 378 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 379 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 380 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 381 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 382 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 383 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 384 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 385 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 386 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 387 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 388 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 389 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 390 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 391 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 392 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 393 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 394 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 395 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 396 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 397 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 398 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 399 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 400 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 401 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 402 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 403 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 404 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 405 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 406 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 407 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 408 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 409 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 410 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 411 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 412 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 413 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 414 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 415 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 416 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 417 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 418 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 419 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 420 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 421 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 422 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 423 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 424 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 425 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
  • TABLE 426 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 427 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 428 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 429 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 430 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 431 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 432 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 433 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 434 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 435 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 436 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 437 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 438 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 439 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 440 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 441 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 442 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
  • TABLE 443 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 444 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
  • TABLE 445 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
  • TABLE 446 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 447 OVERVIEW OF STRATEGIES DEPLOYED BY KEY AUTOINJECTOR DEVICE MANUFACTURING COMPANIES, JANUARY 2021-JANUARY 2025
  • TABLE 448 AUTOINJECTOR DEVICES MARKET: DEGREE OF COMPETITION
  • TABLE 449 AUTOINJECTOR FINISHED FORMULATIONS MARKET: DEGREE OF COMPETITION
  • TABLE 450 AUTOINJECTOR DEVICES MARKET: REGION FOOTPRINT
  • TABLE 451 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REGION FOOTPRINT
  • TABLE 452 AUTOINJECTOR DEVICES MARKET: USAGE FOOTPRINT
  • TABLE 453 AUTOINJECTOR FINISHED FORMULATIONS MARKET: USAGE FOOTPRINT
  • TABLE 454 AUTOINJECTOR DEVICES MARKET: VOLUME FOOTPRINT
  • TABLE 455 AUTOINJECTOR DEVICES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
  • TABLE 456 AUTOINJECTOR FINISHED FORMULATIONS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
  • TABLE 457 AUTOINJECTORS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 458 AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
  • TABLE 459 AUTOINJECTORS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-JANUARY 2025
  • TABLE 460 AUTOINJECTORS MARKET: DEALS, JANUARY 2021- JANUARY 2025
  • TABLE 461 AUTOINJECTORS MARKET: EXPANSIONS, JANUARY 2021- JANUARY 2025
  • TABLE 462 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS
  • TABLE 463 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS
  • TABLE 464 FORMULATION AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS
  • TABLE 465 SHL MEDICAL AG: COMPANY OVERVIEW
  • TABLE 466 SHL MEDICAL AG: PRODUCTS OFFERED
  • TABLE 467 SHL MEDICAL AG: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 468 SHL MEDICAL AG: DEALS, JANUARY 2021-JULY 2024
  • TABLE 469 SHL MEDICAL AG: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 470 YPSOMED AG: COMPANY OVERVIEW
  • TABLE 471 YPSOMED AG: PRODUCTS OFFERED
  • TABLE 472 YPSOMED AG: PRODUCT LAUNCHES, JANUARY 2021-JULY 2024
  • TABLE 473 YPSOMED AG: DEALS, JANUARY 2021-JULY 2024
  • TABLE 474 YPSOMED AG: EXPANSIONS, JANUARY 2021-JULY 2024
  • TABLE 475 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
  • TABLE 476 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
  • TABLE 477 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2021-JULY 2024
  • TABLE 478 BECTON, DICKINSON AND COMPANY (BD): OTHER DEVELOPMENTS, JANUARY 2021- DECEMBER 2024
  • TABLE 479 RECIPHARM AB: COMPANY OVERVIEW
  • TABLE 480 RECIPHARM AB: PRODUCTS OFFERED
  • TABLE 481 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
  • TABLE 482 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 483 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2021- DECEMBER 2024
  • TABLE 484 PHILLIPS-MEDISIZE: COMPANY OVERVIEW
  • TABLE 485 PHILLIPS-MEDISIZE: PRODUCTS OFFERED
  • TABLE 486 PHILLIPS-MEDISIZE: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 487 HALOZYME, INC.: COMPANY OVERVIEW
  • TABLE 488 HALOZYME, INC.: PRODUCTS OFFERED
  • TABLE 489 OWEN MUMFORD LTD.: COMPANY OVERVIEW
  • TABLE 490 OWEN MUMFORD LTD.: PRODUCTS OFFERED
  • TABLE 491 OWEN MUMFORD LTD.: PRODUCT LAUNCHES, JANUARY 2021- DECEMBER 2024
  • TABLE 492 OWEN MUMFORD LTD.: DEALS, JANUARY 2021- DECEMBER 2024
  • TABLE 493 OWEN MUMFORD LTD.: EXPANSIONS, JANUARY 2021- DECEMBER 2024
  • TABLE 494 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 495 ABBVIE INC.: PRODUCTS OFFERED
  • TABLE 496 ABBVIE INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- DECEMBER 2024
  • TABLE 497 ELI LILLY AND COMPANY: COMPANY OVERVIEW
  • TABLE 498 ELI LILLY AND COMPANY: PRODUCTS OFFERED
  • TABLE 499 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021- DECEMBER 2024
  • TABLE 500 ELI LILLY AND COMPANY: DEALS, JANUARY 2021- DECEMBER 2024
  • TABLE 501 AMGEN INC.: COMPANY OVERVIEW
  • TABLE 502 AMGEN INC.: PRODUCTS OFFERED
  • TABLE 503 AMGEN INC.: PRODUCT LAUNCHES, JANUARY 2021- DECEMBER 2024
  • TABLE 504 NOVO NORDISK A/S: COMPANY OVERVIEW
  • TABLE 505 NOVO NORDISK A/S: PRODUCTS OFFERED
  • TABLE 506 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2021- DECEMBER 2024
  • TABLE 507 NOVO NORDISK A/S: DEALS, JANUARY 2021- DECEMBER 2024
  • TABLE 508 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2021- DECEMBER 2024
  • TABLE 509 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2021-DECEMBER 2024
  • TABLE 510 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
  • TABLE 511 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 512 SANOFI: COMPANY OVERVIEW
  • TABLE 513 SANOFI: PRODUCTS OFFERED
  • TABLE 514 GSK PLC: COMPANY OVERVIEW
  • TABLE 515 GSK PLC: PRODUCTS OFFERED
  • TABLE 516 GSK PLC: PRODUCT APPROVALS, JANUARY 2021- DECEMBER 2024
  • TABLE 517 GERRESHEIMER AG: COMPANY OVERVIEW
  • TABLE 518 HASELMEIER: COMPANY OVERVIEW
  • TABLE 519 SMC LTD: COMPANY OVERVIEW
  • TABLE 520 KALEO, INC.: COMPANY OVERVIEW
  • TABLE 521 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW
  • TABLE 522 ELCAM DRUG DELIVERY DEVICES: COMPANY OVERVIEW
  • TABLE 523 CROSSJECT: COMPANY OVERVIEW
  • TABLE 524 JABIL INC.: COMPANY OVERVIEW
  • TABLE 525 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW
  • TABLE 526 MIDAS PHARMA GMBH: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 AUTOINJECTORS MARKET: SEGMENTS CONSIDERED
  • FIGURE 2 AUTOINJECTORS MARKET: YEARS CONSIDERED
  • FIGURE 3 AUTOINJECTORS MARKET: RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS): AUTOINJECTORS MARKET
  • FIGURE 5 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH)
  • FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: REVENUE SHARE ANALYSIS
  • FIGURE 7 ILLUSTRATIVE EXAMPLE OF YPSOMED AG: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 8 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH)
  • FIGURE 9 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: REVENUE SHARE ANALYSIS
  • FIGURE 10 ILLUSTRATIVE EXAMPLE OF ABBVIE INC.: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 11 AUTOINJECTORS MARKET: MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 12 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 13 AUTOINJECTOR DEVICES MARKET SIZE ESTIMATION
  • FIGURE 14 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS (2024-2030)
  • FIGURE 15 AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS (2024-2030)
  • FIGURE 16 DATA TRIANGULATION METHODOLOGY
  • FIGURE 17 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 18 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024 VS. 2030 (MILLION UNITS)
  • FIGURE 19 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2024 VS. 2030 (USD BILLION)
  • FIGURE 20 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2030 (USD MILLION)
  • FIGURE 21 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2030 (USD BILLION)
  • FIGURE 22 AUTOINJECTOR DEVICES MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
  • FIGURE 23 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2024 VS. 2030 (USD BILLION)
  • FIGURE 24 AUTOINJECTOR DEVICES MARKET: REGIONAL SNAPSHOT
  • FIGURE 25 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REGIONAL SNAPSHOT
  • FIGURE 26 INCREASING REGULATORY APPROVALS FOR FINISHED FORMULATION DRUGS TO PROPEL MARKET GROWTH
  • FIGURE 27 US AND DISPOSABLE AUTOINJECTORS DOMINATED MARKET IN 2023
  • FIGURE 28 US AND SUBCUTANEOUS ROUTE OF ADMINISTRATION COMMANDED LARGER MARKET SHARE IN 2023
  • FIGURE 29 RHEUMATOID ARTHRITIS TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 30 MANUAL AUTOINJECTORS ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 31 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030
  • FIGURE 32 ASIA PACIFIC TO COMMAND HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 33 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 34 REVENUE SHIFT AND POCKETS FOR AUTOINJECTOR PROVIDERS
  • FIGURE 35 AUTOINJECTOR DEVICES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 36 AUTOINJECTOR FINISHED FORMULATIONS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 37 AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 38 AUTOINJECTORS MARKET: ECOSYSTEM MAP
  • FIGURE 39 AUTOINJECTORS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 40 PATENT APPLICATIONS IN AUTOINJECTORS MARKET, JANUARY 2014-JANUARY 2025
  • FIGURE 41 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE (2021-2023)
  • FIGURE 42 AVERAGE SELLING PRICE TREND, BY USAGE (2021-2023)
  • FIGURE 43 KEY STAKEHOLDERS IN BUYING PROCESS FOR PHARMACEUTICAL COMPANIES (AUTOINJECTOR DEVICES)
  • FIGURE 44 KEY STAKEHOLDERS IN BUYING PROCESS FOR HOSPITALS (AUTOINJECTOR FINISHED FORMULATIONS)
  • FIGURE 45 KEY BUYING CRITERIA FOR AUTOINJECTOR DEVICES AMONG END USERS
  • FIGURE 46 KEY BUYING CRITERIA FOR AUTOINJECTOR FINISHED FORMULATIONS AMONG END USERS
  • FIGURE 47 AUTOINJECTORS MARKET: IMPACT OF GEN AI
  • FIGURE 48 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT (2023)
  • FIGURE 49 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SNAPSHOT (2023)
  • FIGURE 50 EUROPE: AUTOINJECTOR DEVICES MARKET SNAPSHOT
  • FIGURE 51 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET SNAPSHOT
  • FIGURE 52 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2021-2023)
  • FIGURE 53 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET (2021-2023)
  • FIGURE 54 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2023)
  • FIGURE 55 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET (2023)
  • FIGURE 56 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 57 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 58 AUTOINJECTOR DEVICES MARKET: COMPANY FOOTPRINT
  • FIGURE 59 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY FOOTPRINT
  • FIGURE 60 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 61 EV/EBITDA OF KEY VENDORS
  • FIGURE 62 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 63 AUTOINJECTOR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 64 YPSOMED AG: COMPANY SNAPSHOT (2023)
  • FIGURE 65 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2024)
  • FIGURE 66 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 67 HALOZYME, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 68 ABBVIE INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 69 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 70 AMGEN INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 71 NOVO NORDISK A/S: COMPANY SNAPSHOT (2023)
  • FIGURE 72 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 73 SANOFI: COMPANY SNAPSHOT (2023)
  • FIGURE 74 GSK PLC: COMPANY SNAPSHOT (2023)